Subcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma.

Launched by UNIVERSITY HOSPITAL, TOULOUSE · Apr 17, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the use of specialized fat cells, known as adipose-derived stromal cells (AdMSC), injected under the skin to help heal painful sores on the fingers called digital ulcers in people with scleroderma, a condition that affects the skin and connective tissues. These ulcers can be very difficult to treat and can significantly reduce a person's ability to use their hands and enjoy daily activities. The trial compares the effectiveness and safety of these injections against a placebo (a harmless substance with no active treatment) to see if they can help heal these stubborn ulcers.

To participate in this study, individuals must be at least 18 years old and diagnosed with scleroderma, specifically having at least one active and hard-to-treat digital ulcer. Participants should be over 50 years old, not currently using hormone replacement therapy, and must meet other health criteria. Those who join the study will receive either the AdMSC treatment or a placebo, and they will be closely monitored throughout the process. This trial is important because it could provide a new treatment option for patients who struggle with severe digital ulcers that don’t respond to standard care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female patient ≥18 years of age,
• • Patient with systemic sclerosis according to the 2013 ACR/EULAR classification criteria9,
• • SSc patient with at least one refractory active ischemic digital ulcer at "inclusion visit" (see below the eligibility conditions of a DU),
• • Age \> 50 years and not treated with any kind of hormone replacement therapy for at least 2 years prior to screening, with amenorrhea for at least 24 consecutive months prior to screening. An assessment of serum follicle stimulating hormone showing a level of \> 40 TU/L at screening may be used to exclude childbearing potential, based on the discretion of the investigator,
• • Patient must have provided written informed consent prior to enrolment,
• • Patient must be able to understand their requirements of participating in the protocol,
• • Patient affiliated to a social security system.
• * Relative to each DU :
• The DU at " inclusion visit " must show all the following characteristics:
• • 1. Located beyond the proximal interphalangeal joint, on finger surface (included periungual ulcers),
• • 2. Of ischemic origin according to the physician,
• • 3. Not over subcutaneous calcifications or bone relief,
• • 4. Active DU,
• • 5. Refractory after 10±2 weeks of standard of care according to EULAR recommendations26 (that is either still active (chronic) or new occurrence despite standard of care)
• Exclusion Criteria:
• • Current smoker or tobacco consumption stopped for less than 3 months prior to inclusion, - Patient participating in a clinical trial or having participated in a clinical trial within the previous 3 months,
• • Patients on statins, who have received treatment for less than 3 months prior to Screening or whose treatment has not been stable during this period,
• • Patients on vasodilators, such as endothelin receptor antagonists (ERAs), PDE5 inhibitors (e.g. sildenafil, tadalafil), calcium channel blockers, ACE-inhibitors, nitroglycerin, alpha adrenergic blockers, or angiotensin II receptor antagonists, N-acetylcysteine, antiplatelet aggregation therapy and low molecular weight heparin who have received treatment if present for less than 3 months prior to "inclusion visit" or whose treatment has not been stable for at least 1 month prior to "inclusion visit",
• • Treatment with disease modifying agents such as methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, Interferons and cyclophosphamide, those drugs should be stop at least 1 month prior study entry.
• • Treatment with oral corticosteroids (\> 10 mg/day of prednisone or equivalent),
• • Systemic antibiotics (oral and TV) to treat infected DU(s) within 4 weeks prior to "inclusion visit",
• • Use of topical growth factors, hyperbaric oxygen,
• • Local injection of botulinum toxin in an affected finger within 4 weeks prior to "inclusion visit",
• • Surgical sympathectomy of the upper limbs or surgical wound debridement within 1 month prior to "inclusion visit",
• • Liposuction technically impossible,
• • Patient who underwent autologous hematopoietic stem cell transplantation (HSCT) within less than 1 year,
• • Patients with an indication for intensification by autologous HSCT (according to EBMT guidelines and national RCP MATHEC),
• • History of cancer in the last five years, except for successfully excised basal cell/squamous cell carcinoma, or successfully excised early melanoma of the skin. Subjects, who had successfully tumor resection or radiation or chemotherapy more than 5 years from inclusion and no recurrence, may be enrolled in the study, - Subjects who have active proliferative retinopathy,
• • Positive HIV-1 or 2, HTLV-1 or 2, HBV or HCV,
• • Patients with a history of stroke, myocardial infarction or severe arrhythmia in the last 6 months
• • Patient who had severe cardiac failure in the last 6 months,
• • Females who are pregnant or breastfeeding or plan to do so during the course of this study,
• • Patient under judicial protection, - Refusal of the patient to participate in the study.
• * Relative to each DU:
• • 1. Digital ulcer due to conditions other than scleroderma,
• • 2. Non ischemic digital ulcer,
• • 3. Ulcers with osteomyelitis, or clinically uncontrolled infection,
• • 4. Infected digital ulcer requiring systemic antibiotherapy,
• • 5. Digital ulcer requiring urgent surgery.